Pars Planitis Treatment Market Report 2026

The pars planitis treatment market size has grown strongly in recent years. It will grow from $683.54 billion in 2025 to $737.86 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to improved understanding of uveitis pathophysiology, availability of corticosteroid-based therapies, expansion of ophthalmology specialty clinics, increasing diagnostic imaging utilization, growing clinical awareness of pars planitis.

The pars planitis treatment market size is expected to see strong growth in the next few years. It will grow to $989.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing adoption of personalized ophthalmic treatments, rising demand for long-term inflammation control, expansion of biologic drug pipelines, growing focus on vision preservation strategies, increasing investment in advanced ophthalmic diagnostics. Major trends in the forecast period include increasing use of immunomodulatory therapies, rising adoption of biologic agents, growing preference for targeted anti-inflammatory treatments, expansion of advanced ocular surgical techniques, enhanced focus on early diagnosis and disease monitoring.

The increasing prevalence of pars planitis is expected to drive the growth of the pars planitis treatment market going forward. Pars planitis is an idiopathic form of intermediate uveitis that primarily causes inflammation in the vitreous and peripheral retina, typically affecting individuals aged 15 to 40 years. The rise in pars planitis cases is attributed to growing awareness and improved diagnostic capabilities, as advanced imaging technologies enable earlier and more accurate detection. Treatments for pars planitis help manage the condition by reducing ocular inflammation, making them essential for preserving vision and preventing complications. They improve patient care by providing targeted therapies such as corticosteroids and immunosuppressants, enhancing long-term eye health and quality of life. For instance, in February 2025, according to a case report published by the Mega Journal of Case Reports, a US-based medical journal, intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with idiopathic forms such as pars planitis accounting for 70% of the cases. Therefore, the increasing prevalence of pars planitis is driving the growth of the pars planitis treatment market.

Major companies operating in the pars planitis treatment market are focusing on developing innovative solutions, such as bispecific antibodies, to improve immune modulation, reduce ocular inflammation, and minimize systemic side effects. Bispecific antibodies are engineered proteins designed to bind simultaneously to two different antigens or targets, providing more precise and effective treatment with fewer side effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, received FDA approval for Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion (RVO), in addition to age-related macular degeneration and diabetic macular edema. Vabysmo is the first bispecific antibody approved for ophthalmic use, targeting both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) to address inflammation and vascular leakage simultaneously. This novel mechanism is being explored for intermediate uveitis, including pars planitis, where chronic peripheral retinal inflammation requires durable, targeted intervention.

In May 2023, Alimera Sciences, a US-based healthcare and pharmaceutical company, acquired the U.S. commercial rights to YUTIQ from EyePoint Pharmaceuticals, Inc. for an undisclosed amount. Through this acquisition, Alimera aimed to expand and consolidate its U.S. retinal disease portfolio and leverage its commercial infrastructure to drive product utilization, revenue growth, and deeper market penetration of sustained-release ophthalmic therapies. EyePoint Pharmaceuticals, Inc. is a US-based biopharmaceutical company specializing in ophthalmic drug-delivery technologies and the developer of YUTIQ.

Major companies operating in the pars planitis treatment market are Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Quantum Cryogenics Ltd, Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Roche Holding AG, Pfizer Inc, Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, UCB SA, Bausch Health Companies Inc.

North America was the largest region in the pars planitis treatment market in 2025. The regions covered in the pars planitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pars planitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pars planitis treatment market by increasing costs of imported biologic drugs, corticosteroid implants, ophthalmic surgical instruments, and diagnostic imaging equipment. Hospitals and specialty eye clinics in North America and Europe are most affected due to reliance on advanced imported therapeutics and devices, while Asia-Pacific faces affordability challenges for specialized treatments. These tariffs are increasing treatment expenses and procurement timelines. However, they are also supporting regional pharmaceutical manufacturing, localized production of ophthalmic devices, and broader adoption of cost-optimized treatment protocols.

The pars planitis treatment market research report is one of a series of new reports that provides pars planitis treatment market statistics, including pars planitis treatment industry global market size, regional shares, competitors with a pars planitis treatment market share, detailed pars planitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pars planitis treatment industry. This pars planitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pars planitis treatment involves medical and surgical interventions aimed at managing pars planitis, a chronic intermediate uveitis that affects the pars plana region of the eye, causing inflammation and potential vision impairment. The primary goal of treatment is to reduce ocular inflammation, prevent complications such as macular edema or retinal detachment, and preserve visual function.

The primary treatment types of pars planitis include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), surgery, cryotherapy, immunomodulatory therapy, and others. Corticosteroids are anti-inflammatory medications that mimic hormones produced by the adrenal glands to reduce swelling, suppress the immune system, and manage inflammation-related conditions. Diagnosis methods include blood tests, X-rays, magnetic resonance imaging (MRI), and others, while treatments are administered orally, intravenously, and through other routes. These therapies are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as clinics, hospitals, and others.

The pars planitis treatment market consists of revenues earned by entities by providing services such as diagnosis, pharmacological therapies, surgical interventions, and supportive care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The pars planitis treatment market also includes sales of immunosuppressants, intraocular steroid implants, surgical equipment, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.